e8vk
 

 
 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15 (d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):     February 22, 2005

United Therapeutics Corporation

(Exact Name of Registrant as Specified in Charter)
         
Delaware   000-26301   52-1984749
         
(State or Other   (Commission   (I.R.S. Employer
Jurisdiction of   File Number)   Identification Number)
Incorporation)        
     
1110 Spring Street    
Silver Spring, MD   20910
     
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code:

(301) 608-9292

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
    o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
    o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
    o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

Item 2.02. Results of Operations and Financial Condition.

On February 22, 2005, United Therapeutics Corporation (the “Company”) issued a press release setting forth its earnings for the Company’s quarterly fiscal period and year ended December 31, 2004. A copy of this press release is attached hereto as Exhibit 99.1. The Company does not intend for Exhibit 99.1 to be incorporated by reference into filings under the Securities Act of 1933 or the Securities Exchange Act of 1934.

Item 9.01. Exhibits

     (c) Exhibits

     
Exhibit No.  
Description of Exhibit
 
    
99.1
  Press release dated February 22, 2005

 

 

SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

             
    UNITED THERAPEUTICS CORPORATION
 
            
 
            
Dated: February 22, 2005 
  By:   /s/ Paul A. Mahon    
           
  Name:   Paul A. Mahon    
  Title:   General Counsel    

 

 

EXHIBIT INDEX

     
Exhibit No.  
Description of Exhibit
 
    
99.1
  Press release dated February 22, 2005